Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00219986 · ClinicalTrials.gov registry record · Phase 1
Phase I/II, Open-Label Trial of Three Monoclonal Antibodies
A Phase 1 study, sponsored by Rockefeller University.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00219986 is a Phase 1 study that has completed, run by Rockefeller University. The registered enrollment target is 12 participants.
The verdict
NCT00219986, a Phase 1 study, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
Monoclonal antibody infusions will prevent rebound of viremia in well-suppressed HAART-treated individuals who began therapy during acute and early HIV-1 infection.
Interventions
- DRUG Potent HAART during acute or early HIV-1 infection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2003-10 |
| Est. Completion | 2005-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00219986
The ClinicalTrials.gov registry entry for NCT00219986 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rockefeller University, which has 117 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Potent HAART during acute or early HIV-1 infection is the first listed.
NCT00219986 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00219986 about?
NCT00219986 is a clinical study titled "Phase I/II, Open-Label Trial of Three Monoclonal Antibodies". Monoclonal antibody infusions will prevent rebound of viremia in well-suppressed HAART-treated individuals who began therapy during acute and early HIV-1 infection.
What is the current status of trial NCT00219986?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2003-10. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00219986?
The interventions under investigation include: Potent HAART during acute or early HIV-1 infection (DRUG).
Who is sponsoring clinical trial NCT00219986?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.